Metformin Viatris

Metformin Hydrochloride, the active ingredient in Metformin Viatris, is a biguanide presented as an oral dosage form for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus. GNH USA supplies Metformin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Viatris belongs to the biguanide class and is indicated for the management of hyperglycaemia in type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels.

Metformin Viatris may cause a range of adverse reactions.

Common Side Effects: - Diarrhoea: loose stools occurring especially after dose initiation. - Nausea: feeling of sickness or urge to vomit. - Abdominal discomfort: cramping or pain in the stomach area. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: accumulation of lactate leading to metabolic acidosis, a medical emergency. - Vitamin B12 deficiency: may develop with long‑term therapy, causing neuropathy. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: rare liver injury presenting with jaundice or elevated enzymes.

Metformin Viatris requires careful patient assessment and monitoring. - Renal function: evaluate eGFR before starting and periodically thereafter. - Hepatic function: monitor liver enzymes, especially in patients with existing liver disease. - Risk of lactic acidosis: avoid in patients with hypoxia, severe heart failure, or uncontrolled infection. - Alcohol consumption: limit intake as it may increase lactate production. - Pregnancy and lactation: assess risk‑benefit ratio before use. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain diuretics (e.g., furosemide): may impair renal clearance of metformin.

Moderate Interactions (Monitor Closely): - Sulfonylureas: combined therapy may increase risk of hypoglycaemia. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Oral contraceptives: may modestly increase metformin levels; observe for gastrointestinal upset.